AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

RHYTHM BIOSCIENCES LTD

0.057

0.000

Volume:326.08K

Turnover:19.05K

Market Cap:16.19M

PE:-6.44

High:0.060

Open:0.060

Low:0.056

Close:0.057

Loading ...

Overview Company News Filings

Rhythm Biosciences Launches Genetype Pilot With Australia's Top Pathology Provider

MT Newswires Live

Strategic Genetype Pilot with Leading Australian Pathology-RHY.AX

Change in substantial holding - Otto Buttula-RHY.AX

Change in substantial holding-RHY.AX

BRIEF-Rhythm Biosciences Receives Tranche Of A$1M In Non-Dilutive Funding From Endpoints Capital

Rhythm Biosciences Ltd - Received Tranche of a$1M in Non-Dilutive Funding From Endpoints Capital

THOMSON REUTERS

ASX ALERT-FY2025 R&D Tax Incentive Loan Funding-RHY.AX

Rhythm Biosciences Secures Reinstatement of Accreditation for Cancer Risk Assessment Portfolio; Shares Down 3%

MT Newswires Live

ASX ALERT-NATA Accreditation Awarded for Genetype Laboratory-RHY.AX

Ceasing to be a substantial holder-RHY.AX

Rhythm Biosciences Chairman Resigns, Successor Named

MT Newswires Live

BRIEF-Rhythm Biosciences Says Gavin Fox-Smith To Assume Role Of Chairman

Rhythm Biosciences Ltd - Gavin Fox-Smith to Assume Role of Chairman at 2025 AGM

THOMSON REUTERS

Board Composition Update Succession Plan-RHY.AX

Rhythm Biosciences Publishes Advanced Colorectal Cancer Risk Model

MT Newswires Live

Rhythm Biosciences Ltd-Proposed Issue of Securities - Rhy

THOMSON REUTERS

Rhythm Biosciences' Unit Partners With University of Melbourne for Breast Cancer Risk Assessment Study

MT Newswires Live

Rhythm Biosciences Ltd-Proposed Issue of Securities - Rhy

THOMSON REUTERS

Rhythm Biosciences Receives Quality Certification from UK Standards Body

MT Newswires Live

Rhythm Biosciences Unit Records First Commercial Sales

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RHY.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHY.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","market":"AU","secType":"STK","nameCN":"RHYTHM BIOSCIENCES LTD","latestPrice":0.057,"timestamp":1752732720000,"preClose":0.057,"halted":0,"volume":326083,"delay":0,"nameEN":"RHYTHM BIOSCIENCES LTD","floatShares":210785718,"shares":284080621,"eps":-0.008853,"marketStatus":"Not Yet Opened","change":0,"latestTime":"07-17 16:12:00 AEST","open":0.06,"high":0.06,"low":0.056,"amount":19054,"amplitude":0.070175,"askPrice":0.058,"askSize":40000,"bidPrice":0.057,"bidSize":93527,"shortable":3,"etf":0,"ttmEps":-0.008853,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1752796800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.057,"openAndCloseTimeList":[[1752710400000,1752732000000]],"volumeRatio":1.140008,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","floatShares":210785718,"roa":"-33.68%","roe":"-71.10%","lyrEps":-0.030034,"volumeRatio":1.140008,"shares":284080621,"dividePrice":0,"high":0.06,"amplitude":0.070175,"preClose":0.057,"low":0.056,"week52Low":0.042,"pbRate":"3.32","psRate":"5.11","week52High":0.14,"institutionHeld":0,"latestPrice":0.057,"committee":0.40087,"eps":-0.008853,"divideRate":0,"volume":326083,"delay":0,"ttmEps":-0.008853,"open":0.06,"prevYearClose":0.087,"prevWeekClose":0.058,"prevMonthClose":0.054,"prevQuarterClose":0.054,"fiveDayClose":0.058,"twentyDayClose":0.065,"sixtyDayClose":0.076},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHY.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552109743","title":"Rhythm Biosciences Launches Genetype Pilot With Australia's Top Pathology Provider","url":"https://stock-news.laohu8.com/highlight/detail?id=2552109743","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552109743?lang=en_us&edition=fundamental","pubTime":"2025-07-17 15:41","pubTimestamp":1752738087,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said that its Genetype subsidiary business has secured its first strategic pilot partnership with a leading pathology service provider in Australia, advancing the company's predictive cancer diagnostics technology, according to a Thursday Australian bourse filing.The partnership brings dedicated resources from both sides to drive innovation in cancer, coronary, and diabetes risk assessment through personalized medicine, expanding patient access to genotyping tests, and setting the stage for wider commercial deployment and increased revenue potential, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","XKO.AU","XAO.AU","RHY.AU","BK7124"],"gpt_icon":0},{"id":"2552117512","title":"Strategic Genetype Pilot with Leading Australian Pathology-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2552117512","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552117512?lang=en_us&edition=fundamental","pubTime":"2025-07-17 06:47","pubTimestamp":1752706057,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250716:nASX79VbCP","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nASX1TPjmh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2550358683","title":"Change in substantial holding - Otto Buttula-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550358683","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550358683?lang=en_us&edition=fundamental","pubTime":"2025-07-09 14:43","pubTimestamp":1752043409,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nASX9WyV4S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nASX3mSGqh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2548873563","title":"Change in substantial holding-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548873563","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548873563?lang=en_us&edition=fundamental","pubTime":"2025-07-03 15:12","pubTimestamp":1751526777,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250703:nASX2qxMkx","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nASX17rhSx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2547106399","title":"BRIEF-Rhythm Biosciences Receives Tranche Of A$1M In Non-Dilutive Funding From Endpoints Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2547106399","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547106399?lang=en_us&edition=fundamental","pubTime":"2025-06-30 16:19","pubTimestamp":1751271558,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Receives Tranche Of A$1M In Non-Dilutive Funding From Endpoints CapitalJune 30 (Reuters) - Rhythm Biosciences Ltd RHY.AX:RECEIVED TRANCHE OF A$1M IN NON-DILUTIVE FUNDING FROM ENDPOINTS CAPITALFurther company coverage: RHY.AX ((Reuters.Briefs@thomsonreuters.com))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX08U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2547057375","title":"Rhythm Biosciences Ltd -  Received Tranche of a$1M in Non-Dilutive Funding From Endpoints Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2547057375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547057375?lang=en_us&edition=fundamental","pubTime":"2025-06-30 15:29","pubTimestamp":1751268593,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX08U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2547050689","title":"ASX ALERT-FY2025 R&D Tax Incentive Loan Funding-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2547050689","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547050689?lang=en_us&edition=fundamental","pubTime":"2025-06-30 15:29","pubTimestamp":1751268572,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX1wXy9N","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASXt1lQy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2545747617","title":"Rhythm Biosciences Secures Reinstatement of Accreditation for Cancer Risk Assessment Portfolio; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545747617","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545747617?lang=en_us&edition=fundamental","pubTime":"2025-06-24 11:58","pubTimestamp":1750737497,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  secures a reinstatement of its National Association of Testing Authorities accreditation for the geneType cancer risk assessment assay portfolio, according to a Tuesday filing with the Australian bourse.This follows the temporary suspension of the accreditation after the company acquired the geneType assets from Genetic Technologies , the filing said.The reinstatement marks the conclusion of the integration of the geneType laboratory under the company's ownership, per the filing.Shares were down 3% in afternoon trade on Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","GTG.AU","RHY.AU","BK7508","BK7048"],"gpt_icon":0},{"id":"2545498425","title":"ASX ALERT-NATA Accreditation Awarded for Genetype Laboratory-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2545498425","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545498425?lang=en_us&edition=fundamental","pubTime":"2025-06-24 07:17","pubTimestamp":1750720629,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250623:nASXgVLqQ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nASX6B8Kch:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2545467159","title":"Ceasing to be a substantial holder-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2545467159","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545467159?lang=en_us&edition=fundamental","pubTime":"2025-06-23 14:35","pubTimestamp":1750660550,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250623:nASX1yd8nn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nASX5FVLsc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2545688014","title":"Rhythm Biosciences Chairman Resigns, Successor Named","url":"https://stock-news.laohu8.com/highlight/detail?id=2545688014","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545688014?lang=en_us&edition=fundamental","pubTime":"2025-06-23 10:16","pubTimestamp":1750644977,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said that Non-Executive Chairman Otto Buttula plans to step down as both chair and director at the company's current year annual general meeting, according to a Monday Australian bourse filing.Gavin Fox-Smith will succeed Buttula as chairman following his retirement, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XAO.AU","RHY.AU","XJO.AU","BK7124"],"gpt_icon":0},{"id":"2545459031","title":"BRIEF-Rhythm Biosciences Says Gavin Fox-Smith To Assume Role Of Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2545459031","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545459031?lang=en_us&edition=fundamental","pubTime":"2025-06-23 07:54","pubTimestamp":1750636486,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Says Gavin Fox-Smith To Assume Role Of ChairmanJune 23 (Reuters) - Rhythm Biosciences Ltd RHY.AX:GAVIN FOX-SMITH TO ASSUME ROLE OF CHAIRMAN AT 2025 AGMFurther company coverage: RHY.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nFWN3SO03F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2545456023","title":"Rhythm Biosciences Ltd - Gavin Fox-Smith to Assume Role of Chairman at 2025 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2545456023","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545456023?lang=en_us&edition=fundamental","pubTime":"2025-06-23 07:10","pubTimestamp":1750633851,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nFWN3SO03F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2545459600","title":"Board Composition Update Succession Plan-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2545459600","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545459600?lang=en_us&edition=fundamental","pubTime":"2025-06-23 07:10","pubTimestamp":1750633841,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250622:nASX9d8SSY","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nASX9Nv0XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2542956856","title":"Rhythm Biosciences Publishes Advanced Colorectal Cancer Risk Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2542956856","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542956856?lang=en_us&edition=fundamental","pubTime":"2025-06-12 10:55","pubTimestamp":1749696929,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  has introduced an enhanced colorectal cancer risk prediction model based on data from nearly 400,000 individuals in the UK Biobank, with findings published in the scientific journal PLoS One, marking a major step forward for its geneType test, according to a Wednesday filing with the Australian bourse.The new model enhances colorectal cancer risk prediction by incorporating three clinically relevant, easy-to-use risk factors along with sex-specific elements. Designed for commercial application, it balances simplicity and accuracy while emphasizing the importance of lifestyle and clinical factors in assessing multifactorial diseases, per the filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK6088","IE00B66KJ199.SGD","BK7124","IE00B19Z4B17.USD","AEIS","RHY.AU","IE0031619046.USD","BLZ.SI","BK6522","BK4157","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2539292571","title":"Rhythm Biosciences Ltd-Proposed Issue of Securities - Rhy","url":"https://stock-news.laohu8.com/highlight/detail?id=2539292571","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539292571?lang=en_us&edition=fundamental","pubTime":"2025-05-30 08:09","pubTimestamp":1748563740,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUE8WRL3D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2535618688","title":"Rhythm Biosciences' Unit Partners With University of Melbourne for Breast Cancer Risk Assessment Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2535618688","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535618688?lang=en_us&edition=fundamental","pubTime":"2025-05-15 14:25","pubTimestamp":1747290351,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said its unit, geneType, secured a 12-month contract with the University of Melbourne to support a clinical study aimed at improving breast cancer screening through personalized risk assessment, according to a Thursday filing with the Australian bourse.The study will fund additional imaging for high-risk participants, ensuring they receive necessary follow-up care at no personal cost, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2532047567","title":"Rhythm Biosciences Ltd-Proposed Issue of Securities - Rhy","url":"https://stock-news.laohu8.com/highlight/detail?id=2532047567","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532047567?lang=en_us&edition=fundamental","pubTime":"2025-05-01 14:21","pubTimestamp":1746080476,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nTUE7SY5SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2527971450","title":"Rhythm Biosciences Receives Quality Certification from UK Standards Body","url":"https://stock-news.laohu8.com/highlight/detail?id=2527971450","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527971450?lang=en_us&edition=fundamental","pubTime":"2025-04-14 14:25","pubTimestamp":1744611942,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said that it has retained its ISO 13485:2016 certification for the seventh year from the UK's British Standards Institution , according to a Monday filing with the Australian bourse.This year's certification also includes an expanded scope, now covering the design, manufacturing, distribution, installation, and servicing of in-vitro medical devices, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2520110961","title":"Rhythm Biosciences Unit Records First Commercial Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2520110961","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520110961?lang=en_us&edition=fundamental","pubTime":"2025-03-19 09:19","pubTimestamp":1742347152,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said that its Genetype business recorded its first commercial sales under the company's ownership, according to a Wednesday Australian bourse filing.The company said it is forecasting an \"attractive\" sales growth profile for Genetype products over the foreseeable future, driven by potential enterprise customers and support from influential key opinion leaders, among other factors.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RHY.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHY.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-07-27","symbol":"RHY.AU","type":"split","dateTimestamp":1595772000000,"forFactor":875,"toFactor":1000,"ratio":0.875}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHY.AU\",market:\"AU\",,,undefined,":[]}}